<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Epstein, Andrew E.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Stroke Prevention in Atrial Fibrillation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">This article reviews multiple studies that evaluated other pharmacologic agents, as well as discusses three anticoagulation management strategies that can be sued during atrial fibrillation (AF) ablation and methods for assessing and identifying stroke risk in AF patients.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>